Francesco Maria Lavino
Directeur Général chez F2G Ltd.
Postes actifs de Francesco Maria Lavino
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | 12/04/2021 | - |
| Directeur Général | 12/04/2021 | - | |
| F2g Inc. | Directeur/Membre du Conseil | - | - |
| President | - | - |
Historique de carrière de Francesco Maria Lavino
Anciens postes connus de Francesco Maria Lavino
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | 01/09/2015 | 01/07/2017 |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/12/2013 | 01/09/2015 |
| MERCK & CO., INC. | Directeur/Membre du Conseil | 01/01/2011 | 01/11/2013 |
| NABRIVA THERAPEUTICS PLC | Corporate Officer/Principal | 10/07/2017 | - |
Formation de Francesco Maria Lavino
| Università degli Studi di Napoli Federico II | Undergraduate Degree |
| SDA Bocconi School of Management | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 4 |
| Italie | 3 |
| Irlande | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| Sales & Marketing | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NABRIVA THERAPEUTICS PLC | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
| F2g Inc. |
- Bourse
- Insiders
- Francesco Maria Lavino
- Expérience
